Biglycan Promotes Glioma Cell Line Epithelial-Mesenchymal Transition and Temozolomide Resistance in Vitro

Abstract

Gliomas are aggressive brain tumors associated with high mortality and treatment resistance. This study investigates the role of Biglycan (BGN) in glioma progression and its potential as a prognostic marker and therapeutic target. Analysis of data from The Cancer Genome Atlas (TCGA) reveals dysregulated BGN expression in low-grade gliomas (LGG) and glioblastoma (GBM) with positive correlation to tumor grade. High BGN expression is associated with poor prognosis. Functional analysis highlights BGNs involvement in ECM regulation and EMT, driving glioma invasion and drug resistance. Silencing BGN reduces EMT-related gene expression and invasion capacity. Moreover, BGN expression is upregulated upon TMZ treatment, implicating its role in TMZ resistance. Targeting BGN may be a promising strategy to overcome glioma treatment resistance.